Horizon Discovery Group plc interim results for the six months ended 30 June 2014
23 September 2014 | By Horizon Discovery
Horizon Discovery Group plc announces its interim results for the six months ended 30 June 2014...
List view / Grid view
News
Abcam licenses novel Ceefourin inhibitors of multidrug resistance protein 4 from Australia’s Children’s Cancer Institute
22 September 2014 | By Children’s Cancer Institute and Abcam plc
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development...
Sanofi and MyoKardia announce groundbreaking collaboration to develop targeted therapies for patients with genetic heart disease
19 September 2014 | By Sanofi
Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease...
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
19 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, jointly announce an exclusive global license and development collaboration...
Curie-Cancer and Inventiva announce a partnership in epigenetics for the treatment of cancer
16 September 2014 | By Andrew Lloyd & Associates
Curie-Cancer and Inventiva announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR...
Genetic testing can identify men at six-fold increased risk of prostate cancer
15 September 2014 | By The Institute of Cancer Research, London
Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease...
Scientific founder of Intercept Pharmaceuticals joins Tiziana Life Sciences
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
Oxford Global’s Drug Discovery USA Congress 2014 new hot topics released & regsitration is closing soon
11 September 2014 | By Oxford Global Conferences
Oxford Global Conferences are proud to present the Drug Discovery USA Congress, taking place on 21 – 22 October at the Hyatt Boston Harbor Hotel, Boston, USA...
Waters unveils global mass spectrometry headquarters in the UK’s North West
11 September 2014 | By Waters
Waters Corporation (NYSE: WAT) today celebrated the official opening of its new, custom-built mass spectrometry headquarters in Wilmslow, UK, confirming the company's commitment to innovation and the expanded usage of mass spectrometry...
Ario Pharma acquires PharmEste’s TRPA1 research assets
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
DPT Laboratories acquires Meda Pharmaceuticals’ Lakewood, New Jersey, Location
11 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
27 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
Pfizer and MSD to collaborate on study evaluating novel anti-cancer combination regimen
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
Initiation of Phase 3 trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
AstraZeneca advances tralokinumab to Phase III in severe asthma
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
